Pratia Pardubice a.s.
- Address
- lock Available on a paid plan
Immune System Diseases
The chronic pain department at Pratia Pardubice a.s. conducts studies targeting immune system diseases such as rheumatoid arthritis, psoriatic arthritis and plaque psoriasis, aiming to evaluate new biologic therapies and improve patient outcomes.
- Rheumatoid arthritis treatment efficacy
- Psoriatic arthritis symptom reduction
- Plaque psoriasis therapeutic advances
- Biologic drug safety assessment
These trials help refine therapeutic strategies for autoimmune conditions while supporting the site’s commitment to innovative care.
Musculoskeletal Diseases
Research at this site focuses on musculoskeletal diseases, particularly joint inflammation and pain associated with rheumatoid arthritis and gout, seeking to compare novel agents with established standards.
- Joint inflammation control
- Gout management with urate‑lowering therapy
- Assessment of disease activity scores
- Optimizing pain relief protocols
The work contributes to better management of musculoskeletal disorders and enhances quality of life for affected patients.
Nutritional and Metabolic Diseases
The department investigates nutritional and metabolic diseases, exemplified by studies on gout with hyperuricemia, to determine the effectiveness of new uric‑acid‑lowering treatments.
- Hyperuricemia reduction strategies
- Comparison of tigulixostat versus allopurinol
- Metabolic impact of gout therapies
- Safety profiling of novel agents
Findings aim to provide clearer guidance for clinicians managing metabolic aspects of gout.
Pathological Conditions, Signs and Symptoms
Studies under the umbrella of pathological conditions, signs and symptoms address chronic pain and disease activity monitoring, evaluating how emerging treatments affect overall symptom burden.
- Chronic pain assessment tools
- Disease activity score (DAS28‑ESR) changes
- Patient‑reported outcome improvements
- Safety and tolerability of investigational drugs
This research supports a holistic approach to symptom management across multiple disease states.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 15 of 45 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +12 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Pratia Pardubice a.s.
lock Showing 1 of 52 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 22104: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Active Psoriatic Arthritis | Acelyrin Inc. | Phase IV | Not Recruiting | Apr 2023 | Oct 2024 |
IMP list
lock Showing 1 of 45 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Paracetamol | 5 | Unknown | 2024-02-13 | 2025-04-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.